Record overview
Status and phase
Status: NOT_YET_RECRUITING
Phase: PHASE2
Sponsor: Shanghai Henlius Biotech
Condition: Breast Cancer (Triple Negative Breast Cancer (TNBC))
NCT07487519
Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: few_sites_large_trial_signal | rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.